omniture

Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities

Huifeng Bio-Pharmaceutical Technology, Inc.
2008-05-15 20:10 979


XI’AN, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that there was no damage incurred to their facilities as a result of the Sichuan Earthquake.

Immediately following the earthquake, local Xi’an government officials ordered all workers sent home. However, the company is pleased to announce that the Government has since allowed the workers to return to the facilities and operations have resumed with only a minimal delay to production.

“We are terribly saddened by the loss of life and property in the Sichuan Earthquake. While we are happy to report that neither our employees nor our facilities suffered any harm, Huifeng is prepared to provide support to the victims of this terrible disaster,” stated company CEO Jing’An Wang. “As of this time, operations at Huifeng have returned to normal and all employees are back at work.”

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi’an, People’s Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/

For more information, please contact:

Dan Carlson,

Primary Capital LLC

Tel: +1-415-460-1165

Email: DCarlson@PrimaryLLC.com

Source: Huifeng Bio-Pharmaceutical Technology, Inc.
collection